Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News ProtoKinetix Inc PKTX

Healthcare Biotechnology
ProtoKinetix, Incorporated is a research and development stage biotechnology company. The Company is focused on scientific medical research of Anti-Freeze Glycoproteins (AFGPs) or anti-aging glycoproteins. The Company’s anti-aging glycopeptide is for ophthalmology, dermatology, transplant support and biomanufacturing. The commercial applications for AAGPs include various health care solutions... see more

Recent & Breaking News (OTCQB:PKTX)

ProtoKinetix AAGP® Dry Eye Therapy Testing Results

Business Wire January 6, 2020

ProtoKinetix AAGP® Retinal Cell Replacement Therapy Testing at UBC Completed

Business Wire December 19, 2019

ProtoKinetix AAGP® Dry Eye Therapy Program Launched

Business Wire November 22, 2019

ProtoKinetix AAGP® Operational Update

Business Wire November 6, 2019

Tests Show AAGP® Preserved and Enabled Retinal Cells to Mature Without Compromise after 5-Month Milestone

Business Wire August 23, 2019

ProtoKinetix Reaches Mid-Point of 3rd Stage of Retinal Cell Replacement Therapy Testing at UBC

Business Wire July 9, 2019

ProtoKinetix Achieves Primary Objective Safety at Midpoint of Clinical Trial

Business Wire June 7, 2019

ProtoKinetix First in Series of Town Hall Shareholder Meetings

Business Wire May 30, 2019

Agreement Secured by ProtoKinetix to Start Heart Research Product Validation Studies

Business Wire May 9, 2019

ProtoKinetix Discusses Investor Awareness Campaign and Recent Market Activity

Business Wire May 6, 2019

ProtoKinetix AAGP® in Phase 3 Retinal Replacement Program

Business Wire April 23, 2019

ProtoKinetix Releases Third in a Series of Scientific Update Videos

Business Wire February 26, 2019

ProtoKinetix Releases Second in a Series of Scientific Update Videos

Business Wire January 16, 2019

ProtoKinetix Releases First in a Series of Scientific Update Videos

Business Wire December 19, 2018

ProtoKinetix Begins Cardiovascular Research

Business Wire September 28, 2018

ProtoKinetix AAGP® Molecule Moving Forward in Key Healthcare Studies Targeting Important Health Care Solutions

Business Wire September 4, 2018

ProtoKinetix Enters into 3rd Phase of Retinal Cell Replacement Therapy Testing at UBC

Business Wire August 10, 2018

ProtoKinetix’s AAGP® Signs a Material Transfer Agreement with a Reputed International Biotech Company

Business Wire June 13, 2018

ProtoKinetix Has Entered into a Research Agreement with The University of British Columbia to Test the Effect of its AAGP™ on Monoclonal Antibody Production and Bone Marrow Recovery

Business Wire January 10, 2018

The Effects of ProtoKinetix’ Anti-Aging Glycopeptide (AAGP™) on Immune Cell Banking and Functions Relevant to Immunotherapy

Business Wire November 16, 2017